Huge breakthrough for oncology as scientists nail lung-cancer gene
For 40 years researchers have tried to block a mutant gene. They’ve now done so with a drug the FDA has approved
Amgen’s lung-cancer treatment sotorasib has won approval from US regulators, becoming the first therapy to target a tumour-stoking genetic mutation scientists have tried to block for decades.
The Food and Drug Administration (FDA) clearance, while only for a small group of patients, is a milestone for oncology. The drug is the first to directly target a mutant gene called KRAS G12C that’s present in about 13% of non-small-cell lung cancers.
KRAS is a growth-promoting gene that’s mutated in numerous lung, colon and pancreatic tumours. The mutations cause a key protein to send constant signals for cells to grow and proliferate...